Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.

about

Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole - First Case Report and another Example of an Immunocompromised District.

Item

http://www.wikidata.org/entity/Q52684197

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Segmental Erythema Multiforme- ...... an Immunocompromised District.

@en

Segmental Erythema Multiforme- ...... an Immunocompromised District.

@nl

type

Item

label

Segmental Erythema Multiforme- ...... an Immunocompromised District.

@en

Segmental Erythema Multiforme- ...... an Immunocompromised District.

@nl

prefLabel

Segmental Erythema Multiforme- ...... an Immunocompromised District.

@en

Segmental Erythema Multiforme- ...... an Immunocompromised District.

@nl

P1476

Segmental Erythema Multiforme- ...... an Immunocompromised District.

@en

P2093

Birgit Heinig

http://www.w3.org/2001/XMLSchema#string

Georgi Tchernev

http://www.w3.org/2001/XMLSchema#string

Jacqueline Schönlebe

http://www.w3.org/2001/XMLSchema#string

Katlein França

http://www.w3.org/2001/XMLSchema#string

P2860

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

Life-threatening acute adverse cutaneous drug reactions.

Lupus erythematosus: uncommon presentations.

Cutaneous vasculitis in breast cancer treated with chemotherapy.

Erythema nodosum secondary to aromatase inhibitor use in breast cancer patients: case reports and review of the literature.

Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.

Aromatase inhibitor-induced skin adverse reactions: exemestane-related cutaneous vasculitis.

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT000

A case series of erythema multiforme-like pityriasis rosea.

Cutaneous vasculitis developed in a patient with breast cancer undergoing aromatase inhibitor treatment.

P304

79-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.3889/OAMJMS.2018.026

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Uwe Wollina

Torello Lotti

P577

2018-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29483990

http://www.w3.org/2001/XMLSchema#string

P932

5816324

http://www.w3.org/2001/XMLSchema#string